TAE684 (NVP-TAE684)

Catalog No.S1108

TAE684 (NVP-TAE684) Chemical Structure

Molecular Weight(MW): 614.2

TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR.

Size Price Stock Quantity  
USD 160 In stock
USD 290 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (A) H3122 xenografts harboring the EML4-ALK translocation were treated with control vehicle or the ALK inhibitor, TAE-684, for 2 days; the tumors were excised and lysates were prepared. The TIMM results for the control and treated animals are shown. (B) H3122 cells were treated in the presence or absence of TAE-684 (100 nM) for 6 hours in the presence or absence of the indicated ligands [EGF (50 ng/mL), IGF1 (50 ng/mL), and HGF (50 ng/mL)]. Extracts were probed with the indicated antibodies.

    Cancer Res 2011 71, 4920-31. TAE684 (NVP-TAE684) purchased from Selleck.

    Therapeutic effects of ALK inhibitor TAE684 on H694R- and E1384K-mediated tumorigenesis of H1299 transfectants. (B) Dosage effects of TAE684 on phospho-Y1604 ALK expression of wild-type, H694R, and E1384K transfectants by Western blot analysis (top panel). Quantitative results of phospho-Y1604 ALK intensity are also (bottom panel).

    Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck.

  • Therapeutic effects of ALK inhibitor TAE684 on H694R- and E1384K-mediated tumorigenesis of H1299 transfectants. (C) Suppressive effects of TAE684 on H694R- and E1384K-induced tumors in vivo. Photographs and tumor growth curves are shown in the top and bottom panels, respectively (four mice per group).

    Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck.

    Therapeutic effects of ALK inhibitor TAE684 on H694R- and E1384K-mediated tumorigenesis of H1299 transfectants. (A) Dosage effects of TAE684 on H694R- and E1384K-induced cell proliferation measured with WST-1 activity. 

    Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck.

Purity & Quality Control

Choose Selective ALK Inhibitors

Biological Activity

Description TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR.
Targets
ALK [1]
(Cell-free assay)
3 nM
In vitro

TAE684 does not exhibit significant cross-reactivity against other kinases. TAE684 potently inhibits the proliferation of Ba/F3 NPM-ALK cells with IC50 of 3 nM, without affecting the survival of Ba/F3 cells even at 1 μM. TAE684 also inhibits proliferation of NPM-ALK-expressing human ALCL cell lines including Karpas-299 and SU-DHL-1 with IC50 of 2–5 nM. Molecular modeling reveals that L258 may be one of the major kinase-selectivity determinants for TAE684. TAE684 treatment results in a rapid and sustained inhibition of phosphorylation of NPM-ALK. TAE684 induces apoptosis and G1 phase arrest in NPM-ALK-expressing Ba/F3 cells and ALCL patient cell lines. [1] TAE684 markedly overcomes Crizotinib-resistance in H3122 CR cells, harboring the fusion oncogene EML4-ALK, decreasing cell growth, suppressing ALK phosphorylation and inducing apoptosis.[2] Neurite outgrowth induced by expression of the mALK R1279Q mutant could be completely inhibited by TAE684 at 30 nM. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 M2HWWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2WzWmlEPTB;MD6wNFAxPjB|IN88US=> M4HkOnNCVkeHUh?=
SF539 MonOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUP3R2tDUUN3ME2wMlAxODV4NDFOwG0> M4jqTHNCVkeHUh?=
DEL NYPZbXZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ewPWlEPTB;MD6wNFA6OjdizszN NFPtT4hUSU6JRWK=
NB1 NXPVR|h7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT5eHBKSzVyPUCuNFAyPjJizszN M4DQcHNCVkeHUh?=
SR NV;rfop4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\N[YZKSzVyPUCuNFAzPzdizszN MU\TRW5ITVJ?
KARPAS-299 NGCw[I5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDWXHVKSzVyPUCuNFI{QDRizszN MWPTRW5ITVJ?
MHH-CALL-2 Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1O2Z2lEPTB;MD6wNlk2OiEQvF2= MWfTRW5ITVJ?
SU-DHL-1 NXTxco5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HkVGlEPTB;MD6wOFg3PSEQvF2= M1jJWHNCVkeHUh?=
A4-Fuk NGKyfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\QTWM2OD1yLkC1OVY2KM7:TR?= NHfpd|ZUSU6JRWK=
EW-1 NGLEfIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnT[VhKSzVyPUCuNVAzPTZizszN M1jNPHNCVkeHUh?=
NOS-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHXVYJKSzVyPUCuNVAzQTRizszN M1;1OXNCVkeHUh?=
EW-16 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzybI1KSzVyPUCuNVA2PjhizszN Mn3XV2FPT0WU
TE-11 M16zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjITWM2OD1yLkG2NFk3KM7:TR?= Ml2wV2FPT0WU
SW982 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PVWmlEPTB;MD6xOlQ4QCEQvF2= MoDSV2FPT0WU
LAN-6 NXTMNG4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLWS3ZKSzVyPUCuNVc1PDNizszN NYrueGx5W0GQR1XS
MZ1-PC M1Tn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoO1TWM2OD1yLkG3PFM2KM7:TR?= MkXMV2FPT0WU
KS-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n5cGlEPTB;MD6xPVM1OyEQvF2= NVOycFhIW0GQR1XS
PSN1 NHTXeHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwMUm2N|Eh|ryP MlvvV2FPT0WU
LC-2-ad NXi1T5J6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwMUm2PVIh|ryP MlT1V2FPT0WU
COLO-320-HSR NVL1S3E6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4W4dWlEPTB;MD6xPVc4PiEQvF2= MmLxV2FPT0WU
OPM-2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;VcmlEPTB;MD6yNlY3QSEQvF2= NIP5WXVUSU6JRWK=
SK-NEP-1 NHXI[GxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlO3TWM2OD1yLkKzOVI1KM7:TR?= MoPmV2FPT0WU
ALL-PO MmnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwMkS1NlQh|ryP NGD6N|VUSU6JRWK=
CMK M{ftU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrjZ2NKSzVyPUCuNlU2OyEQvF2= NYGz[ZZ3W0GQR1XS
NCI-H1648 NVr2WZJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2G3OWlEPTB;MD6yO|g2PSEQvF2= NFLX[JhUSU6JRWK=
SIG-M5 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3nTWM2OD1yLkK5NVU6KM7:TR?= MkDVV2FPT0WU
TGBC24TKB NV\WU5poT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3P5UGlEPTB;MD6zNFIyQCEQvF2= M{DVRnNCVkeHUh?=
DOHH-2 M3jXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnITWM2OD1yLkOxNlA1KM7:TR?= NUL6flJnW0GQR1XS
NB69 MnTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrOc4ZKSzVyPUCuN|E4QDdizszN Mk\IV2FPT0WU
MFH-ino M3v4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwM{K1NlMh|ryP NHOwNIZUSU6JRWK=
KP-N-RT-BM-1 MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwM{OxNlMh|ryP M2T3OnNCVkeHUh?=
MONO-MAC-6 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3YWZF2UUN3ME2wMlM{OjlzIN88US=> NFXLO|lUSU6JRWK=
ATN-1 MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwM{OzNFMh|ryP M3jaenNCVkeHUh?=
NTERA-S-cl-D1 M1jzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFra[plKSzVyPUCuN|M{QTZizszN NEnwbWFUSU6JRWK=
L-540 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwM{[5PFgh|ryP NH7JWVlUSU6JRWK=
GB-1 Mn7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwM{i4Olch|ryP MY\TRW5ITVJ?
MV-4-11 M{TNWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwM{m0OFYh|ryP NV3zUlRpW0GQR1XS
KG-1 M3\odmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\iTWM2OD1yLkO5OVYyKM7:TR?= MnvhV2FPT0WU
OVCAR-4 MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXQTWM2OD1yLkSwOVY6KM7:TR?= MlLoV2FPT0WU
NEC8 NVfjfYplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3y0WGlEPTB;MD60NVI6OiEQvF2= Mm\UV2FPT0WU
SK-MM-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwNEG2NFkh|ryP MWrTRW5ITVJ?
TE-8 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1T3fGlEPTB;MD60Nlg5KM7:TR?= MoPFV2FPT0WU
697 NWjHPY95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTIOZk6UUN3ME2wMlQ{OjF3IN88US=> MUXTRW5ITVJ?
NB14 M1fQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwNEO4NlYh|ryP MkPRV2FPT0WU
GDM-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13yVmlEPTB;MD60O|EyPiEQvF2= MlPQV2FPT0WU
HUTU-80 M2jCeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XhTGlEPTB;MD60O|M4PSEQvF2= M4nuRXNCVkeHUh?=
HL-60 NYqzc2lGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13HbGlEPTB;MD60PFE1OiEQvF2= NGXDO2RUSU6JRWK=
OCI-AML2 MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml6xTWM2OD1yLkS4N|I5KM7:TR?= M3vybHNCVkeHUh?=
ML-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LvVWlEPTB;MD60PVA{OSEQvF2= MWPTRW5ITVJ?
ES4 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MluxTWM2OD1yLkS5NVA6KM7:TR?= NWXrVGFoW0GQR1XS
NCI-H747 NFHKUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1P5ZWlEPTB;MD60PVg6KM7:TR?= NVX5emlZW0GQR1XS
RL95-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fqVWlEPTB;MD61NFEyOiEQvF2= NXjjTYlJW0GQR1XS
TE-15 M1W4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrXS21KSzVyPUCuOVEyOjRizszN NIDkeo1USU6JRWK=
TE-12 NWHk[VhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DYUWlEPTB;MD61N|M1QSEQvF2= MWXTRW5ITVJ?
LB1047-RCC NHq1TlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\YTnVKSzVyPUCuOVQ2PDlizszN NEP6S|JUSU6JRWK=
LB831-BLC MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwNUWwNlMh|ryP NHrvPZpUSU6JRWK=
NCI-H1355 MmPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HYeGlEPTB;MD61OVE5PCEQvF2= M4G5XXNCVkeHUh?=
CTV-1 NX\xOJc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwNUW2NlQh|ryP MYDTRW5ITVJ?
RXF393 MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTGb4hKSzVyPUCuOVU4QTRizszN M4ThfnNCVkeHUh?=
SW872 MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVO5c4tkUUN3ME2wMlU3PzJ2IN88US=> NHvCbplUSU6JRWK=
MPP-89 MnTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vCUWlEPTB;MD61O|g5PCEQvF2= NWjSWXU5W0GQR1XS
RPMI-8226 M4TiWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[4N2lEPTB;MD62N|UzPiEQvF2= MYfTRW5ITVJ?
LS-1034 NID3VZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwNkO1PEDPxE1? NWjmflVVW0GQR1XS
SJSA-1 M4PBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3kdGxUUUN3ME2wMlY{PzJ3IN88US=> M1zLVHNCVkeHUh?=
HOP-62 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwNkWwN|Mh|ryP MlLBV2FPT0WU
KGN NXy0Unp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXWVG9KSzVyPUCuOlYyPjhizszN NUfwZodOW0GQR1XS
D-336MG MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7VTWM2OD1yLk[2NVY6KM7:TR?= MoXDV2FPT0WU
LS-411N MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7BTWM2OD1yLk[3OFYzKM7:TR?= MlTqV2FPT0WU
TE-1 MlX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwNkmwO|Qh|ryP NEjtSmVUSU6JRWK=
LB996-RCC NYDESIZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHL5dHZKSzVyPUCuOlk{QDlizszN NH3OZlJUSU6JRWK=
TE-10 MmTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwN{G0PVYh|ryP NYXYVFFCW0GQR1XS
NCI-SNU-16 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTJ[VNQUUN3ME2wMlczPjZ2IN88US=> NWTGeI94W0GQR1XS
ES8 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{WyUmlEPTB;MD63OFk4PSEQvF2= NHvOU5JUSU6JRWK=
COLO-800 M3TEbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fvN2lEPTB;MD63OlY6PSEQvF2= NYW0RnJZW0GQR1XS
ES6 NH[ycoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnndYp5UUN3ME2wMlc4PTV7IN88US=> MX\TRW5ITVJ?
L-363 M4DVTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmewTWM2OD1yLkiyN|c2KM7:TR?= M3jPTXNCVkeHUh?=
NMC-G1 M3G3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwOEOyN|Mh|ryP MWDTRW5ITVJ?
LU-134-A MkDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\uTJdKSzVyPUCuPFM6OTJizszN M2rZSHNCVkeHUh?=
SF268 M3GzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwOESwOFIh|ryP NF76S|VUSU6JRWK=
KARPAS-45 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrwU3hKSzVyPUCuPFQzPjNizszN NYDSV|B4W0GQR1XS
TGW Mki1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwOEW4OlMh|ryP MUnTRW5ITVJ?
CHP-126 Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwOEW5OVch|ryP MofsV2FPT0WU
MOLT-16 NWnUVoFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\ZUXlPUUN3ME2wMlg4PTh7IN88US=> MVTTRW5ITVJ?
LB771-HNC NWrMTWpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfGTWM2OD1yLki5O|U4KM7:TR?= NWjV[Gg1W0GQR1XS
NALM-6 NYPOVlZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYH0clZ1UUN3ME2wMlkxPzN7IN88US=> MlPyV2FPT0WU
GCIY NVXoTm9jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HmWGlEPTB;MD65OVUzPiEQvF2= MY\TRW5ITVJ?
IST-MES1 MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPOTWM2OD1yLkm4PFI1KM7:TR?= M13HTnNCVkeHUh?=
LB2241-RCC M4\BNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPuRZZKSzVyPUCuPVg5PCEQvF2= MnPsV2FPT0WU
BL-70 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTpeVFNUUN3ME2wMlk6PTN3IN88US=> NUXG[JBpW0GQR1XS
NB17 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H1XGlEPTB;MT6wNFY{QSEQvF2= NYK2OmFCW0GQR1XS
LXF-289 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HFZ2lEPTB;MT6wN|A4PiEQvF2= M1LxTXNCVkeHUh?=
TK10 MnrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHLTWM2OD1zLkC1NFY{KM7:TR?= MlO5V2FPT0WU
K5 NETyV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTIToZKSzVyPUGuNFYzPzRizszN M3;0VXNCVkeHUh?=
NCI-H716 M3;mOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDnTWM2OD1zLkC3NlU6KM7:TR?= NHjrRmlUSU6JRWK=
HCE-T MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTFwMEi4NVkh|ryP NIDkT2RUSU6JRWK=
GI-1 NFfyNJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;XOoVyUUN3ME2xMlA6Pzl6IN88US=> MkPyV2FPT0WU
KARPAS-422 NXfTXWVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFwMUCwNlIh|ryP NU\6eXdYW0GQR1XS
TE-9 NVKzeHprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7qbI1yUUN3ME2xMlEyOzJ6IN88US=> MlOxV2FPT0WU
SF126 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTJU5JKSzVyPUGuNVE2PjhizszN M{iwdXNCVkeHUh?=
BB30-HNC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfkcpRKSzVyPUGuNVMyOTJizszN MnTJV2FPT0WU
NCI-H1304 NYm2eHRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXzS3RtUUN3ME2xMlE{OzN6IN88US=> NYrVPWQ2W0GQR1XS
HEL NHHIVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\NeJdnUUN3ME2xMlE1QDl3IN88US=> NWqzelAxW0GQR1XS
HAL-01 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTFwMUWyPFMh|ryP M{j1VnNCVkeHUh?=
SK-LMS-1 NUWxWGliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojDTWM2OD1zLkG1PVc1KM7:TR?= NUnQUmpIW0GQR1XS
SW954 NVroNWhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTFwMUm1Olch|ryP M3[xfnNCVkeHUh?=
D-283MED NVPoOI5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fSXWlEPTB;MT6yNlM4QSEQvF2= MWfTRW5ITVJ?
NCI-H1882 NWrOcm1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTFwMkO4PUDPxE1? NGW4eoJUSU6JRWK=
GI-ME-N MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTFwMkWyNFgh|ryP NYThS4Q4W0GQR1XS
SK-PN-DW M362VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3oeWN4UUN3ME2xMlI3OzR6IN88US=> M1f0e3NCVkeHUh?=
C2BBe1 NHq1ZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGCxU4dKSzVyPUGuNlkyOTdizszN MX3TRW5ITVJ?
A704 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoD6TWM2OD1zLkOyOlg6KM7:TR?= NUHYPXRkW0GQR1XS
KALS-1 M1fLcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rIWWlEPTB;MT6zOFA5KM7:TR?= M2DM[nNCVkeHUh?=
ETK-1 Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYr1dHJzUUN3ME2xMlM1PDh7IN88US=> NIrZOW9USU6JRWK=
LB647-SCLC M3zVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTFwM{S5PFYh|ryP MkPGV2FPT0WU
OCUB-M MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\oWpRKSzVyPUGuN|YyPDNizszN NGraN4VUSU6JRWK=
NCI-H720 MmW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnSSXVPUUN3ME2xMlM3Ozd6IN88US=> MWPTRW5ITVJ?
NB13 M4Cz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7mcWtKSzVyPUGuN|czQTNizszN Mk\CV2FPT0WU
GR-ST M3\FU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:xOYNPUUN3ME2xMlM5PzV5IN88US=> NIjqT3pUSU6JRWK=
DU-4475 NFHtRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fBSWlEPTB;MT60OVg2OyEQvF2= NHXvTppUSU6JRWK=
HCC2157 NUHWNIVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33VXmlEPTB;MT60OlY2QSEQvF2= Mk\EV2FPT0WU
RKO M2LmbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfFRoE2UUN3ME2xMlQ6QTJ{IN88US=> NVzo[XFWW0GQR1XS
LS-123 NVXDVmYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVW3flFpUUN3ME2xMlUyPTl2IN88US=> MV7TRW5ITVJ?
NCI-H69 Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYH4R4M2UUN3ME2xMlU2QDFzIN88US=> MX7TRW5ITVJ?
SW962 NF\zdXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonPTWM2OD1zLkW2NVMh|ryP NUnNendNW0GQR1XS
PF-382 M1zQdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nudWlEPTB;MT61Olk3KM7:TR?= NUi4U5BbW0GQR1XS
A101D NGDiPWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIq3[ZlKSzVyPUGuOVcyOTNizszN NYn3RnhrW0GQR1XS
NB10 NF7kN5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LRVGlEPTB;MT61O|M6OiEQvF2= NG[3WZRUSU6JRWK=
NB5 NUizeJpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfnTWM2OD1zLkW4OFc3KM7:TR?= NEjFemdUSU6JRWK=
HCE-4 MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PrNWlEPTB;MT62NFg2KM7:TR?= Mk\yV2FPT0WU
HT-144 NIHFflVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTFwNkOxPUDPxE1? NX7UclZWW0GQR1XS
NCI-H524 NGjqfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnJTWM2OD1zLk[0N|A4KM7:TR?= Mm\UV2FPT0WU
NKM-1 M1XmN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTFwNki2OkDPxE1? NYn4R|hJW0GQR1XS
KURAMOCHI M1XHb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fiOGlEPTB;MT62PVU4OyEQvF2= MVrTRW5ITVJ?
NCI-H187 MoXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfsZlJKSzVyPUGuO|AxOzZizszN M3f6fnNCVkeHUh?=
U-266 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\ITWM2OD1zLkezPFQzKM7:TR?= MnnuV2FPT0WU
BL-41 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4GwUWlEPTB;MT63OlI4OiEQvF2= Mn;XV2FPT0WU
SK-N-DZ MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTFwN{izNFkh|ryP MVTTRW5ITVJ?
Daudi MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTjSYtKSzVyPUGuO|g6PjdizszN MonYV2FPT0WU
CPC-N NIrCTmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTFwOEWwPVYh|ryP NUDiNnFKW0GQR1XS
EM-2 NUHLW5BvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[y[WlEPTB;MT64OVEh|ryP MnL3V2FPT0WU
HCC1187 M4THZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLqXWFOUUN3ME2xMlg3OjRzIN88US=> NFjmb4tUSU6JRWK=
LP-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfYSXZKSzVyPUGuPFcyPDNizszN MVXTRW5ITVJ?
CAS-1 NY[0XGFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTFwOUiyPVkh|ryP MXfTRW5ITVJ?
NB7 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17mSGlEPTB;Mj6wNFU2PSEQvF2= NGnmUFhUSU6JRWK=
VA-ES-BJ NWrH[YlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTJwMEG1NVMh|ryP NFuxVWxUSU6JRWK=
SNU-C2B NVTiNohZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInvdJpKSzVyPUKuNFM{PTFizszN M3;6b3NCVkeHUh?=
LOXIMVI NIHXPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFO0fpRKSzVyPUKuNFY4QDZizszN MWfTRW5ITVJ?
NCI-H1581 Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MomxTWM2OD1{LkGxOVU6KM7:TR?= NYDVcWZOW0GQR1XS
IST-SL2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zvXmlEPTB;Mj6xNlQ1PSEQvF2= MWHTRW5ITVJ?
NOMO-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTJwMUe2PFMh|ryP MljFV2FPT0WU
TE-6 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJwMUmwOUDPxE1? MlHBV2FPT0WU
NCI-H526 NIDobIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[3dllCUUN3ME2yMlE6OTRzIN88US=> NHP6fpNUSU6JRWK=
MSTO-211H NW\2enlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlr6TWM2OD1{LkKwNFQyKM7:TR?= NUC0OJFuW0GQR1XS
LS-513 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojQTWM2OD1{LkKyNlY6KM7:TR?= MX7TRW5ITVJ?
NCI-SNU-1 Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELTSXFKSzVyPUKuN|MzPTZizszN MWPTRW5ITVJ?
BB65-RCC NIPVe4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{W0dWlEPTB;Mj6zO|Q6OyEQvF2= M2P1fXNCVkeHUh?=
GT3TKB M2nhTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTiTWM2OD1{LkO5PVczKM7:TR?= NVToZpFiW0GQR1XS
OS-RC-2 MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrzTWM2OD1{LkSyN|QyKM7:TR?= MVvTRW5ITVJ?
NCI-H2126 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoW4TWM2OD1{LkSzOlc1KM7:TR?= NGT4c5lUSU6JRWK=
SK-UT-1 M1TXZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkflTWM2OD1{LkS3OFY4KM7:TR?= Mm\wV2FPT0WU
DMS-114 NV[1Tot2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTUXZhnUUN3ME2yMlYyPTJ2IN88US=> MUXTRW5ITVJ?
ONS-76 M4m2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDlUodKSzVyPUKuOlM3PDFizszN Ml;pV2FPT0WU
8-MG-BA NXGz[ms1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\RVWlEPTB;Mj62OVQyPCEQvF2= MYfTRW5ITVJ?
BOKU MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTJwN{K3OlQh|ryP NVLlNWpRW0GQR1XS
LAMA-84 M1XTZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTJTWM2OD1{Lke5PVEzKM7:TR?= Mk[3V2FPT0WU
ES1 MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoqxTWM2OD1{LkixPFA1KM7:TR?= NYPBfVl7W0GQR1XS
NCI-H1395 NEPHT2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIntTnFKSzVyPUKuPFIxOTJizszN MWLTRW5ITVJ?
A388 NEj2eZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PnTGlEPTB;Mj65OlE4KM7:TR?= MX;TRW5ITVJ?
NCCIT MlTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojYTWM2OD1|LkC4PFYzKM7:TR?= M2nxNnNCVkeHUh?=
HD-MY-Z MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjtTWM2OD1|LkGzNlA{KM7:TR?= MmDyV2FPT0WU
NCI-H510A NVXSPJNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTNwMUi5OFMh|ryP MofhV2FPT0WU
NCI-N87 NIPlWVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmS4TWM2OD1|LkKwNFIh|ryP NIfQNYlUSU6JRWK=
SCLC-21H NX:xbWJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTNwMk[4OVkh|ryP MkDzV2FPT0WU
SH-4 NXfJPGZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTNwMki3PVch|ryP M2rsUXNCVkeHUh?=
QIMR-WIL NETNV5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnibnU5UUN3ME2zMlMzQDR7IN88US=> MnXOV2FPT0WU
KM12 M1\VcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfiTWM2OD1|LkOzOVQ1KM7:TR?= M2G1ZXNCVkeHUh?=
ST486 NFLmepJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\hbZFKSzVyPUOuOVM5QDNizszN MoDrV2FPT0WU
HC-1 M2HBNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLxWVRuUUN3ME2zMlYzODJ6IN88US=> MV7TRW5ITVJ?
BV-173 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLzdY1pUUN3ME2zMlY1ODh6IN88US=> NFzxcG9USU6JRWK=
EW-24 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XUdmlEPTB;Mz62OlQ{PCEQvF2= Mo\qV2FPT0WU
LU-65 Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTNwNki3NUDPxE1? NYGwV4pnW0GQR1XS
ECC4 M3joZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\lTWM2OD1|Lke3OVYh|ryP NFHs[GtUSU6JRWK=
ARH-77 NIL2W3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTRwMUGwOlch|ryP MlXTV2FPT0WU
BC-3 NILwVIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3WwT2lEPTB;ND6xN|A3QCEQvF2= MVvTRW5ITVJ?
SNB75 NIGzT21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTRwMk[xPUDPxE1? Ml;0V2FPT0WU
MEG-01 MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HwOWlEPTB;ND6yO|QyQSEQvF2= Mn7rV2FPT0WU
NCI-H1417 NFfCWIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXTd4ZEUUN3ME20MlI5PDR|IN88US=> MX7TRW5ITVJ?
MDA-MB-134-VI M{G2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HP[WlEPTB;ND6zNFYxOSEQvF2= NE[1ZlFUSU6JRWK=
Becker M{PJSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHMfohKSzVyPUSuOFc{OzZizszN NW[wV4VrW0GQR1XS
DMS-153 MnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jpZ2lEPTB;ND62OlQ4PSEQvF2= MX7TRW5ITVJ?
TGBC1TKB NWXB[mZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHFTWM2OD12Lk[4OVE2KM7:TR?= MorEV2FPT0WU
EW-3 M3vTPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfmTWM2OD12Lke2NlQ5KM7:TR?= NELrUGVUSU6JRWK=
KE-37 NWPZc5RQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDpPGNKSzVyPUSuPFYyQTZizszN NYrtbWc{W0GQR1XS
NCI-H23 NWLvWFJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXLWWlKSzVyPUSuPFczOjdizszN MUnTRW5ITVJ?
MC116 NXjuSm5yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGSxVXhKSzVyPUSuPVQyOjZizszN MoPTV2FPT0WU
NH-12 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXPTWM2OD12Lkm2OFM6KM7:TR?= Mlv1V2FPT0WU
CTB-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\ZWGlEPTB;ND65O|czOSEQvF2= M4\zUXNCVkeHUh?=
KM-H2 NWrRUHdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvoWIg6UUN3ME21MlA2OzJ|IN88US=> M3;SZnNCVkeHUh?=
MOLT-4 NInHfmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;SV2lEPTB;NT6xNVg{KM7:TR?= NFPzfnNUSU6JRWK=
NCI-H2141 NEm4WW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTVwMUSyOlgh|ryP MofoV2FPT0WU
EB-3 NHjyZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\UUm5KSzVyPUWuNVc2ODRizszN NGHDU2NUSU6JRWK=
NCI-H1522 M{[yTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HwUmlEPTB;NT6yOlMzOiEQvF2= MojUV2FPT0WU
MRK-nu-1 NX[5WHhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTVwNEO2N|Mh|ryP MVLTRW5ITVJ?
no-11 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTVwNEewPFch|ryP NGTJRlhUSU6JRWK=
CESS MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLlOHlrUUN3ME21MlU5ODN2IN88US=> MVjTRW5ITVJ?
KMOE-2 NVzETYh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LteGlEPTB;NT61PFY2QSEQvF2= NF3OcoNUSU6JRWK=
REH M4HhZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\TZYd2UUN3ME22MlI2PjF6IN88US=> M4DmPXNCVkeHUh?=
KU812 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[xcoFIUUN3ME22MlQzPzlzIN88US=> NHHPUpBUSU6JRWK=
SK-N-FI NEWzcJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTZwNkC2O|Qh|ryP M4TvdHNCVkeHUh?=
MMAC-SF MkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTHclVJUUN3ME23MlA3PDl{IN88US=> Mom4V2FPT0WU
RCC10RGB M4DON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTdwMkK5O|ch|ryP M2jxRXNCVkeHUh?=
NCI-H322M NH[0fZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTdwM{OzN|Uh|ryP NGHCd|ZUSU6JRWK=
NB6 M{nud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTmOpdHUUN3ME23MlU1QDl7IN88US=> M1XOSnNCVkeHUh?=
MN-60 NFn6cWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnTRZJKSzVyPUeuOlkzOTVizszN M3vSTnNCVkeHUh?=
NCI-H1092 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRThwMEG3N|Qh|ryP MmrxV2FPT0WU
EKVX NXPvNIlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjFOYVQUUN3ME24MlQ4ODZ4IN88US=> M{HCZXNCVkeHUh?=
D-263MG NWnmcFZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYeyfI9CUUN3ME24MlU2Ozl4IN88US=> M4\lZnNCVkeHUh?=
NCI-H209 MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjYbIVKSzVyPUiuOlQxODZizszN MnezV2FPT0WU
IST-SL1 NHLzfnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPCRlFKSzVyPUiuPFk5QTJizszN MmTpV2FPT0WU
ACN NVjGcWVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXaTWM2OD17LkG5NVU4KM7:TR?= NVTwcm9ZW0GQR1XS
MHH-PREB-1 M4rxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmm4TWM2OD17LkKxNlE6KM7:TR?= M3\FOXNCVkeHUh?=
EW-11 MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MomyTWM2OD17Lk[1N|k3KM7:TR?= MWHTRW5ITVJ?
KASUMI-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnUXVVKSzVyPUmuO|g4PyEQvF2= NUnlNXVHW0GQR1XS
KINGS-1 NWDWWYhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLNTWM2OD1zMD6yN|Q4KM7:TR?= NFrKWVBUSU6JRWK=
EVSA-T M1rNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrkTWM2OD1zMD6zNVkzKM7:TR?= MmrsV2FPT0WU
DSH1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zYdGlEPTB;MUCuN|k4OiEQvF2= NGOxenlUSU6JRWK=
COLO-824 NF74TIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\nfJMxUUN3ME2xNE45PjZ7IN88US=> MonPV2FPT0WU
K052 M{TzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrrcI9CUUN3ME2xNE46OzJ{IN88US=> NX;senZ2W0GQR1XS
SK-MEL-2 M1L4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DVNWlEPTB;MUCuPVk{QSEQvF2= NULXdZdsW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo After 4 weeks of treatment with TAE684 at 3 and 10 mg/kg, there is a significant delay in lymphoma development and 100- to 1,000-fold reduction in luminescence signal, without any signs of compound- or disease-related toxicity in Karpas-299 lymphoma model. TAE684 treatment also induces disease regression in established Karpas-299 lymphomas and down-regulates CD30 expression. [1] TAE684 also shows impressive antitumor activity against H3122 CR xenograft tumors. [2] Furthermore, treatment with TAE684 improves the rough eye phenotype of both ALK mutants, especially that seen with ALKR1275Q, whereas Crizotinib has little effect on either phenotype. [3]

Protocol

Kinase Assay:[1]
+ Expand

In vitro Enzyme Assays.:

All in vitro enzyme assays are done at Upstate Biotechnology with the exception of InsR and IGF-1R. To determine the IC50 of TAE684 against InsR and IGF-1R a homogeneous time-resolved fluorescence assay is performed. ATP (10 mM) and 20 mg/ml biotinylated PolyEY (Glu, Tyr 4:1) are combined with 50 nL of serial dilutions of TAE684 (10-500 nM) and 4 ng of InsR enzyme in the presence of the kinase reaction buffer (20 mM Tris譎Cl, pH 7.5/10 mM MgCl2/3 mM MnCl2/1 mM DTT/10 mM NaVO4/0.1 mg/ml of BSA). Assays are incubated for 1 hour at ambient temperature. Reactions are terminated by adding 10 mL of the detection solution containing 50 mM EDTA, 500 mM KF, 0.5 mg/ml of BSA, 5 mg/mL Eu3+ cryptate-labeled anti-phosphotyrosine antibody Mab PT66-K, and 5 mg/mL Streptavidin-XLent. The reaction is incubated for half an hour, and fluorescence signals are read on Analyst GT.
Cell Research:[1]
+ Expand
  • Cell lines: Luciferase-expressing Karpas-299, SU-DHL-1, and Ba/F3 cells and transformed Ba/F3 stably expressing NPM-ALK, Bcr-Abl, or TEL-kinase fusion constructs.
  • Concentrations: 1 nM-10 μM
  • Incubation Time: 2–3 days
  • Method: Cells are seeded in 384-well plates (2.5×104 cells per well) and incubated with serial dilutions of TAE684 or DMSO for 2–3 days. Luciferase expression is used as a measure of cell proliferation/survival and is evaluated with the Bright-Glo Luciferase Assay System. IC50 values are generated by using XLFit software.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Karpas-299 xenografts are established in 4- to 6-week old female Fox Chase SCIDBeige mice.
  • Formulation: Resuspended in 10% 1-methyl-2-pyrrolidinone/90% polyethylene glycol 300 solution
  • Dosages: 1, 3, and 10 mg/kg
  • Administration: Once daily by oral gavage for 3 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 3 mg/mL (4.88 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol, pH 4 10 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 614.2
Formula

C30H40ClN7O3S

CAS No. 761439-42-3
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ALK Signaling Pathway Map

ALK Inhibitors with Unique Features

Related ALK Products

Tags: buy TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) supplier | purchase TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) cost | TAE684 (NVP-TAE684) manufacturer | order TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID